Premium
Apolipoprotein A1: A new serum marker correlated to JAK2 V617F proportion at diagnosis in patients with polycythemia vera
Author(s) -
Mossuz Pascal,
Bouamrani Ali,
Brugière Sabine,
Arlotto Marie,
Hermouet Sylvie,
Lippert Eric,
Laporte François,
Girodon François,
Dobo Irène,
Vincent Praloran,
Garin Jérome,
Cahn Jean Yves,
Berger François
Publication year - 2007
Publication title -
proteomics – clinical applications
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.948
H-Index - 54
eISSN - 1862-8354
pISSN - 1862-8346
DOI - 10.1002/prca.200601051
Subject(s) - polycythemia vera , jak2 v617f , apolipoprotein b , allele , biology , immunology , medicine , microbiology and biotechnology , mutation , genetics , gene , cholesterol
Polycythemia vera (PV) is a myeloproliferative disorder (MPD) characterized by an acquired gain‐of‐function mutation of the JAK2 protein (JAK2 V617F). Allele‐specific quantitative PCR has showed a JAK2 V617F dosage effect on haematological and clinical parameters of PV at diagnosis, but it is unknown whether the level of certain serum proteins might correlate with the proportion of mutated JAK2. Taking into account that such proteins could represent useful prognostic marker, we investigated the serum protein profile of PV patients by SELDI‐TOF MS. We identified apolipoprotein A1 (Apo‐A1) as a serum marker correlated to the percentage of JAK2 V617F alleles; Apo‐A1 expression being the highest for PV patients with more than 75% of mutated alleles. Immuno‐assay on an automated random immuno‐analyser confirmed the correlation between Apo‐A1 concentrations and JAK2 V617F percentages, and showed that serum Apo‐A1 assay allowed the specific discrimination of PV patients with high levels of mutated alleles (≥75%). These data suggest that Apo‐A1 assay could be a useful assay for the stratification of PV patients at diagnosis.